| Asia after Viet Nam RM Nixon Foreign Aff. 46, 111, 1967 | 678 | 1967 |
| Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or … A van Walsem, S Pandhi, RM Nixon, P Guyot, A Karabis, RA Moore Arthritis research & therapy 17, 1-18, 2015 | 200 | 2015 |
| Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared RM Nixon, D Wonderling, RD Grieve Health economics 19 (3), 316-333, 2010 | 196 | 2010 |
| Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis RM Nixon, N Bansback, A Brennan Statistics in medicine 26 (6), 1237-1254, 2007 | 187 | 2007 |
| The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK M Orme, J Kerrigan, D Tyas, N Russell, R Nixon Value in health 10 (1), 54-60, 2007 | 185 | 2007 |
| Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials M Gomes, ESW Ng, R Grieve, R Nixon, J Carpenter, SG Thompson Medical Decision Making 32 (2), 350-361, 2012 | 155 | 2012 |
| Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations RM Nixon, SG Thompson Health economics 14 (12), 1217-1229, 2005 | 149 | 2005 |
| Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry A Brennan, N Bansback, R Nixon, J Madan, M Harrison, K Watson, ... Rheumatology 46 (8), 1345-1354, 2007 | 145 | 2007 |
| The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons R Nixon, N Bansback, A Brennan Oxford University Press 46 (7), 1140-1147, 2007 | 139 | 2007 |
| Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta‐analytical approach RM Nixon, E Müller, A Lowy, H Falvey International journal of clinical practice 63 (5), 766-775, 2009 | 138 | 2009 |
| Biologic drugs for rheumatoid arthritis in the Medicare program: a cost‐effectiveness analysis AJ Wailoo, N Bansback, A Brennan, K Michaud, RM Nixon, F Wolfe Arthritis & Rheumatism 58 (4), 939-946, 2008 | 129 | 2008 |
| Indicators of undernutrition in cattle S Agenäs, MF Heath, RM Nixon, JM Wilkinson, CJC Phillips Animal Welfare 15 (2), 149-160, 2006 | 125 | 2006 |
| Parametric modelling of cost data in medical studies RM Nixon, SG Thompson Statistics in medicine 23 (8), 1311-1331, 2004 | 121 | 2004 |
| Parametric modelling of cost data: some simulation evidence A Briggs, R Nixon, S Dixon, S Thompson Health economics 14 (4), 421-428, 2005 | 116 | 2005 |
| No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing–remitting multiple sclerosis R Nixon, N Bergvall, D Tomic, N Sfikas, G Cutter, G Giovannoni Advances in therapy 31, 1134-1154, 2014 | 111 | 2014 |
| Longer polyglutamine tracts in the androgen receptor are associated with moderate to severe undermasculinized genitalia in XY males HN Lim, H Chen, S McBride, AM Dunning, RM Nixon, IA Hughes, ... Human Molecular Genetics 9 (5), 829-834, 2000 | 110 | 2000 |
| Costs and quality of life of multiple sclerosis in the United Kingdom G Kobelt, J Berg, P Lindgren, J Kerrigan, N Russell, R Nixon The European Journal of Health Economics 7, 96-104, 2006 | 107 | 2006 |
| How sensitive are cost-effectiveness analyses to choice of parametric distributions? SG Thompson, RM Nixon Medical Decision Making 25 (4), 416-423, 2005 | 102 | 2005 |
| Using multilevel models for assessing the variability of multinational resource use and cost data R Grieve, R Nixon, SG Thompson, C Normand Health economics 14 (2), 185-196, 2005 | 92 | 2005 |
| Bio-pics: a life in pictures E Cheshire Columbia University Press, 2014 | 88 | 2014 |
Richard GrieveProfessor of Health Economics MethodologyAdresse e-mail validée de lshtm.ac.uk
